Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Neurology · Behavioral Variant Frontotemporal Dementia

What Are the End-Stage Symptoms of Behavioral Variant FTD?

At a Glance

End-stage behavioral variant frontotemporal dementia often causes profound apathy, loss of speech, stiffness, slowed movement, and swallowing problems. Families should watch for falls and pneumonia from food or liquid entering the lungs and plan comfort-focused care with clinicians.

The later stages of behavioral variant frontotemporal dementia (bvFTD) mark a significant transition from the active, sometimes disruptive behaviors seen early in the disease to a quieter state of physical and cognitive decline. While every person’s journey is unique and the exact timeline cannot be predicted, families and caregivers may notice a progression toward profound apathy, loss of speech, and movement impairments such as parkinsonism [1][2][3]. Swallowing difficulties (dysphagia) also frequently emerge, which increases the risk of aspiration pneumonia [4][5].

It is important to remember that these changes often develop gradually. However, any sudden or rapid decline in alertness, movement, or behavior should be evaluated promptly by a doctor, as it could indicate a treatable issue like an infection, medication side effect, or dehydration rather than dementia progression [6].

The Shift to Profound Apathy

Early bvFTD is characteristically defined by disinhibition, impulsivity, and compulsive behaviors [7]. However, the disease does not follow a linear path. These active behavioral symptoms frequently decrease or fade over time [1][8].

In advanced stages, apathy—a profound lack of interest, initiative, and emotional response—often becomes the dominant behavioral feature [9][10]. A patient may become entirely dependent on caregivers for daily activities and show little response to their environment [11][12]. This quieter, unengaged state typically reflects ongoing neurodegeneration rather than an improvement in behavior [13].

Progressive Loss of Speech (Mutism)

Communication abilities progressively deteriorate as the disease advances into the brain networks responsible for language [2][14]. Patients may speak less frequently, struggle to find words, or give only brief answers [2]. Ultimately, this progression can lead to mutism, where the person loses the ability to speak verbally [14].

Crucially, a loss of speech does not mean a loss of understanding, feeling, or needs [6]. A person who is mute can still experience pain, distress, or comfort, and may communicate through facial expressions, eye gaze, gestures, or touch. Caregivers should continue to use simple, reassuring language and observe nonverbal cues to assess the person’s needs.

Motor and Movement Issues (Parkinsonism)

As brain tissue loss continues, damage often extends into areas controlling physical movement. Many patients develop parkinsonism—a group of neurological symptoms that includes muscle stiffness (rigidity), slowed movements (bradykinesia), and postural instability leading to falls [3][15].

Unlike classic Parkinson’s disease, the parkinsonism seen in late-stage FTD often affects both sides of the body symmetrically and primarily impacts the core or trunk (axial rigidity) [3]. While it frequently does not improve with common Parkinson’s medications like levodopa, a neurologist may still evaluate the symptoms and trial medications to see if they offer any relief [3]. The emergence of these significant motor impairments is strongly associated with a loss of functional independence and a shorter overall survival time [16][17].

Swallowing Difficulties (Dysphagia) and Aspiration Pneumonia

In the terminal stages, patients often develop dysphagia, or difficulty swallowing [4]. The muscles and reflexes required to safely route food and liquids into the stomach become impaired, especially if the patient has overlapping features of motor neuron disease (like ALS) or bulbar dysfunction (weakness in the muscles of the face and throat) [5][18].

Dysphagia introduces a critical safety risk: aspiration, which happens when food, liquids, or saliva slip into the airway and lungs instead of the stomach [18]. Aspiration increases the risk of developing aspiration pneumonia, a severe lung infection that is a common terminal complication in advanced neurodegenerative diseases [4][5].

Caregivers should watch for signs of unsafe swallowing, such as coughing or choking during meals, a “wet” or gurgly sounding voice, prolonged eating times, or unexplained weight loss and fevers. Because aspiration can also be “silent” (occurring without coughing), a speech-language pathologist should formally evaluate swallowing safety [6]. Do not independently thicken liquids or change food textures without professional guidance. Furthermore, research shows that in advanced dementia, feeding tubes do not reliably prevent aspiration pneumonia or prolong survival; therefore, decisions between careful hand-feeding and artificial nutrition should be based on the patient’s individual goals and clinical situation [6].

Preparing for Palliative Care

Palliative care is specialized medical care focused on minimizing suffering, managing symptoms, and supporting the family, and it can be introduced at any stage alongside other treatments [19]. As the disease reaches its final stages, goals of care frequently transition primarily to comfort [6].

This does not mean all medical care stops. A palliative approach still actively evaluates and treats sources of distress, such as pain, infections, constipation, or medication side effects. Families should work closely with their medical team to establish advance care plans—including a healthcare proxy, preferences for resuscitation, and guidelines for handling respiratory infections or pneumonia when they arise [6][20]. Formal hospice care—a specific type of palliative care for the end of life—may become appropriate when functional dependence and physical vulnerability indicate the patient is in the terminal phase.

Common questions in this guide

What symptoms are common in end-stage behavioral variant frontotemporal dementia?
Later bvFTD often involves profound apathy, very limited or absent speech, stiffness and slowed movement, falls, and difficulty swallowing. The person may become dependent on caregivers for daily activities. Earlier impulsive, disinhibited, or compulsive behaviors may lessen as the disease advances.
If a person with bvFTD stops speaking, can they still understand and feel?
They may still understand language and experience feelings even when they can no longer speak. Loss of speech does not by itself show that the person has lost understanding, comfort, or distress. Continue using simple, reassuring language and look for eye gaze, facial expressions, gestures, and touch to identify needs.
What signs suggest swallowing is becoming unsafe in advanced bvFTD?
Coughing or choking during meals, a wet or gurgly voice, holding food in the mouth, unusually long meals, weight loss, or fevers can signal swallowing difficulty or aspiration. Aspiration can also happen silently without coughing, so a speech-language pathologist should assess swallowing safety. Do not thicken liquids or change food textures without professional guidance.
Could a sudden decline be caused by something other than bvFTD progression?
Any sudden or rapidly worsening change in alertness, movement, or behavior should be assessed promptly by a doctor. Infection, dehydration, or a medication side effect can sometimes cause a treatable decline rather than reflecting dementia progression.
Do feeding tubes prevent pneumonia or extend life in advanced bvFTD?
In advanced dementia, feeding tubes do not reliably prevent aspiration pneumonia or prolong survival. The choice between careful hand-feeding and artificial nutrition should be based on the person's goals, comfort, and clinical situation with guidance from the medical team.
How can late-stage bvFTD affect movement?
Late-stage bvFTD can cause parkinsonism, including stiffness, slowed movements, poor balance, and falls. These problems often affect both sides of the body and may be most pronounced in the trunk. A neurologist can assess symptoms and may try levodopa, although it often provides little benefit in this form of parkinsonism.
When should palliative or hospice care be considered in bvFTD?
Palliative care can begin at any stage to relieve symptoms, support the family, and help with care decisions. In the final stages, the care plan often emphasizes comfort, and hospice may be appropriate when severe dependence and physical vulnerability indicate a terminal phase. Discuss timing and goals with the medical team.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific signs should I watch for to know if swallowing is becoming unsafe or if silent aspiration is occurring?
  2. 2.How can we accurately assess and manage my loved one's pain or discomfort if they become completely mute?
  3. 3.Are there physical therapy, positioning, or nursing interventions that can help manage severe stiffness and prevent bedsores as mobility declines?
  4. 4.What is our plan for handling respiratory infections or pneumonia when they arise, and what does comfort-focused care look like in that scenario?
  5. 5.At what point should we formally consult palliative care or transition to hospice services?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Progression of behavioural disturbances in frontotemporal dementia: a longitudinal observational study.

    Cosseddu M, Benussi A, Gazzina S, et al.

    European journal of neurology 2020; (27(2)):265-272 doi:10.1111/ene.14071.

    PMID: 31448481
  2. 2

    Longitudinal structural and metabolic changes in frontotemporal dementia.

    Bejanin A, Tammewar G, Marx G, et al.

    Neurology 2020; (95(2)):e140-e154 doi:10.1212/WNL.0000000000009760.

    PMID: 32591470
  3. 3

    Parkinsonism in frontotemporal dementias.

    Rowe JB

    International review of neurobiology 2019; (149()):249-275 doi:10.1016/bs.irn.2019.10.012.

    PMID: 31779815
  4. 4

    SQSTM1 variant in disorders of the frontotemporal dementia-amyotrophic lateral sclerosis spectrum: identification of a novel heterozygous variant and a review of the literature.

    Li W, Gao H, Dong X, Zheng D

    Journal of neurology 2021; (268(4)):1351-1357 doi:10.1007/s00415-020-10283-x.

    PMID: 33125541
  5. 5

    Primary progressive aphasia and the FTD-MND spectrum disorders: clinical, pathological, and neuroimaging correlates.

    Vinceti G, Olney N, Mandelli ML, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2019; (20(3-4)):146-158 doi:10.1080/21678421.2018.1556695.

    PMID: 30668155
  6. 6

    FTLD Treatment: Current Practice and Future Possibilities.

    Ljubenkov PA, Boxer AL

    Advances in experimental medicine and biology 2021; (1281()):297-310 doi:10.1007/978-3-030-51140-1_18.

    PMID: 33433882
  7. 7

    Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage.

    Ranasinghe KG, Rankin KP, Lobach IV, et al.

    Neurology 2016; (86(7)):600-10 doi:10.1212/WNL.0000000000002373.

    PMID: 26802093
  8. 8

    Behavioral-variant frontotemporal dementia: Distinct phenotypes with unique functional profiles.

    O'Connor CM, Landin-Romero R, Clemson L, et al.

    Neurology 2017; (89(6)):570-577 doi:10.1212/WNL.0000000000004215.

    PMID: 28701492
  9. 9

    Apathy in Alzheimer's disease and frontotemporal dementia: Distinct clinical profiles and neural correlates.

    Kumfor F, Zhen A, Hodges JR, et al.

    Cortex; a journal devoted to the study of the nervous system and behavior 2018; (103()):350-359 doi:10.1016/j.cortex.2018.03.019.

    PMID: 29704671
  10. 10

    Distinct and shared neuropsychiatric phenotypes in FTLD-tauopathies.

    Keszycki R, Kawles A, Minogue G, et al.

    Frontiers in aging neuroscience 2023; (15()):1164581 doi:10.3389/fnagi.2023.1164581.

    PMID: 37358954
  11. 11

    Apathy, Executive Function, and Emotion Recognition Are the Main Drivers of Functional Impairment in Behavioral Variant of Frontotemporal Dementia.

    Musa Salech G, Lillo P, van der Hiele K, et al.

    Frontiers in neurology 2021; (12()):734251 doi:10.3389/fneur.2021.734251.

    PMID: 35095710
  12. 12

    Apathy and functional disability in behavioral variant frontotemporal dementia.

    Yassuda MS, Lima da Silva TB, O'Connor CM, et al.

    Neurology. Clinical practice 2018; (8(2)):120-128 doi:10.1212/CPJ.0000000000000429.

    PMID: 29708208
  13. 13

    Longitudinal change in everyday function and behavioral symptoms in frontotemporal dementia.

    O'Connor CM, Clemson L, Hornberger M, et al.

    Neurology. Clinical practice 2016; (6(5)):419-428 doi:10.1212/CPJ.0000000000000264.

    PMID: 27847684
  14. 14

    Speech and language impairments in behavioral variant frontotemporal dementia: A systematic review.

    Geraudie A, Battista P, García AM, et al.

    Neuroscience and biobehavioral reviews 2021; (131()):1076-1095 doi:10.1016/j.neubiorev.2021.10.015.

    PMID: 34673112
  15. 15

    Genotype-phenotype correlation in the spectrum of frontotemporal dementia-parkinsonian syndromes and advanced diagnostic approaches.

    Zecca C, Tortelli R, Carrera P, et al.

    Critical reviews in clinical laboratory sciences 2023; (60(3)):171-188 doi:10.1080/10408363.2022.2150833.

    PMID: 36510705
  16. 16

    Predicting loss of independence and mortality in frontotemporal lobar degeneration syndromes.

    Murley AG, Rouse MA, Coyle-Gilchrist ITS, et al.

    Journal of neurology, neurosurgery, and psychiatry 2021; (92(7)):737-744 doi:10.1136/jnnp-2020-324903.

    PMID: 33563798
  17. 17

    Young-onset frontotemporal dementia in a homozygous tau R406W mutation carrier.

    Ng AS, Sias AC, Pressman PS, et al.

    Annals of clinical and translational neurology 2015; (2(12)):1124-8 doi:10.1002/acn3.265.

    PMID: 26734663
  18. 18

    Phenotypic variability in ALS-FTD and effect on survival.

    Ahmed RM, Devenney EM, Strikwerda-Brown C, et al.

    Neurology 2020; (94(19)):e2005-e2013 doi:10.1212/WNL.0000000000009398.

    PMID: 32277059
  19. 19

    Behavioral Variant Frontotemporal Dementia.

    Seeley WW

    Continuum (Minneapolis, Minn.) 2019; (25(1)):76-100 doi:10.1212/CON.0000000000000698.

    PMID: 30707188
  20. 20

    The Evolution of Caregiver Burden in Frontotemporal Dementia with and without Amyotrophic Lateral Sclerosis.

    Hsieh S, Leyton CE, Caga J, et al.

    Journal of Alzheimer's disease : JAD 2016; (49(3)):875-85 doi:10.3233/JAD-150475.

    PMID: 26519438

This page describes advanced bvFTD changes for informational purposes only and does not constitute medical advice. Seek prompt medical evaluation for sudden decline, swallowing problems, breathing symptoms, or suspected infection, and discuss care decisions with the medical team.

Get notified when new evidence is published on Behavioral variant of frontotemporal dementia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.